MOTS-c
MOTS-c may improve insulin sensitivity, shift the body toward burning fat for fuel, and expand mitochondrial capacity — the machinery behind endurance and metabolic flexibility. It works through AMPK, the same pathway exercise activates. Your body makes it every time you train, and it makes less of it every year.
Overview
MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome rather than nuclear DNA — one of a small family called mitochondria-derived peptides, alongside humanin and the SHLPs. It was identified in 2015 by Pinchas Cohen's lab at USC.
It behaves like a hormone your mitochondria release. When cells are under energy demand or metabolic stress, MOTS-c signals through AMPK to change how the body handles glucose and fat.
Key benefits
| Benefit | Description |
|---|---|
| Metabolic function | Improves how cells take up and clear glucose, supporting insulin sensitivity and steadier blood sugar. |
| Fat metabolism | Shifts cells toward burning fatty acids for fuel, improving metabolic flexibility — the ability to switch between fuel sources cleanly. |
| Mitochondrial capacity | Signals existing mitochondria to grow and divide, expanding long-term energy capacity through the same pathway endurance training uses. |
| Physical performance | Associated with better endurance and physical output, most clearly in aerobic work rather than strength. |
| Inflammation | Dampens chronic low-grade inflammatory signaling of the kind linked to aging and metabolic dysfunction. |
| Healthy aging | Targets the age-related decline in your own MOTS-c levels, which tracks with reduced metabolic flexibility and exercise capacity. |
Mechanisms of action
AMPK — AMP-activated protein kinase — is the enzyme cells use to sense low energy and respond to it. It's often called the metabolic master switch because it governs how cells produce, store, and spend energy.
MOTS-c doesn't switch AMPK on directly. It interferes with the folate cycle, causing a molecule called AICAR to accumulate — and AICAR activates AMPK.
Once AMPK is active
Cells pull in more glucose through GLUT4 transporters, supporting insulin sensitivity.
Cells shift toward burning fatty acids for fuel.
Through PGC-1α, existing mitochondria grow and divide — the same pathway endurance training uses.
The chronic low-grade kind associated with metabolic dysfunction.
MOTS-c also travels into the nucleus under stress, where it influences genes tied to antioxidant defense — the retrograde signal, mitochondria reporting their state back to the cell's control center.
Think of a cell as a ship.
Deep down in the hull are the engine rooms — the mitochondria. They burn fuel and make all the power the ship runs on. Way up top is the control room, where the decisions get made.
When the engines start running low, they send a runner up to the control room. That runner is MOTS-c.
The message is simple: stop burning through the easy fuel. Start using what we've got stored away — and we need more engine capacity down here.
The control room listens. The ship starts pulling sugar out of the bloodstream and burning stored fat instead. And the engine rooms begin to grow and split into more engine rooms — they don't get built from scratch, they divide, a bit like the bacteria they descended from.
Your engines send that runner every time you exercise. As the ship gets older, they send fewer of them.
Two different clocks
Existing mitochondria change what they burn. That's a switch, and it flips quickly.
Mitochondria growing and dividing takes time. This is the part people actually want, and it can't be rushed.
Why people call it an exercise mimetic: exercise activates AMPK through the same pathway, and your own MOTS-c rises around 12-fold in muscle tissue after cycling in one human study. The label overpromises. The overlap is real.
Considerations
Most of what's known about MOTS-c comes from cell cultures and animal studies. The mechanism is unusually well mapped for a research peptide — understood down to specific genes — but MOTS-c itself has never been through a human clinical trial.
The closest human data comes from CB4211, a synthetic MOTS-c analog that completed Phase 1. About 20 overweight subjects dosed daily for 30 days: blood sugar and liver enzymes improved, body weight did not change.
Cell and rodent studies tell you a compound can do something. Only human trials tell you it does.
It instructs your body to build and burn. Without raw materials, people commonly feel worse before better.
AMPK and mTOR run inversely. Strong AMPK activation dampens muscle-building signaling.
AMPK activators fall under WADA's metabolic modulators category.
Some evidence suggests men may respond more than women. Barely studied.
Every number in circulation comes from practice and inference, not a trial that tested it.
Degrades faster than most. Storage and sourcing matter more than usual.
What it needs to work
This is the part most guides skip. MOTS-c doesn't supply energy — it instructs your cells to build capacity and change how they burn fuel. Those instructions require raw materials. Signal your body to expand mitochondrial capacity without supplying what that takes, and a plausible outcome is feeling worse rather than better.
AMPK activation increases glucose uptake. Running this pathway hard while low on fuel is a straightforward way to feel flat.
Not a supporting nutrient — an actual physical component of the electron transport chain. Absorption is better with fat.
A cofactor for most ATP-dependent enzymes. ATP functions as Mg-ATP; without magnesium it's largely inert.
The molecule the electron transport chain runs on. NAD+ itself is poorly absorbed orally — NR or NMN are the usual route.
Mitochondria are largely protein. Building more draws on the same amino acid pool as everything else.
Add several at once and feel better, and you won't know which one did it.
The research, in detail
- Muscle & liver cell culturesAMPK activationIncreases glucose uptake through GLUT4 transporters and shifts cells toward burning fat for fuel.
- Rodent modelsInsulin sensitivityImproves insulin signaling and glucose clearance in insulin-resistant rodents. Prevented diet-induced obesity in mice (Lee, Cell Metabolism, 2015).
- Cell models under oxidative stressMitochondrial resilienceHelps maintain membrane potential and ATP output when cells are challenged.
- Macrophage modelsInflammatory signalingLowers pro-inflammatory cytokines including TNF-α and IL-6.
- Fibroblast assaysRepair and longevity pathwaysUpregulates PGC-1α and Nrf2 — genes tied to mitochondrial biogenesis and antioxidant defense.
- Aged micePhysical declineRan longer, gripped harder, and walked better late in life (Reynolds, Nature Communications, 2021).
- Humans — geneticsPerformance associationA natural variant in the MOTS-c sequence tracks with muscle fiber composition and physical performance in people born with it.
- Humans — Phase 1, an analogCB4211Dosed daily for 30 days in about 20 overweight subjects. Blood sugar and liver enzymes improved; body weight did not change.
What it feels like
Not much on any given day. No rush, no stimulant effect, no obvious moment. People who respond describe it as cumulative — steadier energy across the afternoon, workouts that feel slightly more productive after a couple of weeks, appetite that's less erratic.
A common early pattern is feeling good for a few days and then noticeably flat. That timing lines up with the point where the signal starts demanding materials.
Dosing
| Parameter | Reported |
|---|---|
| Commonly reported dose | 5–10 mg |
| Frequency | 2–3x weekly |
| Also reported | Lower daily dosing |
| Cycle length | 4–8 weeks, then off |
| Estimated half-life | ~4–6 hours |
| Route | Subcutaneous |
| Phase 1 analog protocol | Daily, 30 days |
Mixing & storage
MOTS-c is fragile — this matters more than dose
It degrades faster than most peptides, and poor storage is the most common reason a cycle does nothing at all.
Stable long-term. Keep vials sealed until you're ready to reconstitute.
Refrigerate immediately. Shorter usable window than most peptides.
Never leave reconstituted product at room temperature for long.
One vial at a time. Reconstituting several in advance wastes the later ones.
Side effects
Injection site reactions are the headline. Redness, flushing, warmth, itching, sometimes small persistent bumps. This was common enough in the CB4211 trial to pause it in 2018 — researchers suspected some of the compound was lingering at the injection site rather than dispersing.
It appears to be a mast cell and histamine response rather than a true allergy. Injecting slowly, starting at the low end, rotating sites, and an antihistamine beforehand help some people. Other reported effects are mild: occasional post-injection fatigue, headache, appetite shifts early on.
Hives spread beyond the injection site, your face or throat swells, breathing changes, or you feel faint. That's systemic, not local — a different situation entirely.
Sourcing
Because this peptide degrades easily, supplier handling matters more here than almost anywhere else.
Lot number should match your vial. A generic PDF reused across the catalog isn't a COA.
The actual chart, not just a "99%" claim on a graphic. Standard spec is ≥99% purity.
Reported in EU/mg, typically under 0.1. Often missing — that absence is information.
If it arrives warm after days in transit, that's a real problem for this one.
Common questions
Is MOTS-c approved?
No. It's sold as a research compound and has never been through a human clinical trial in its own right.
I felt great, then awful. What happened?
Common pattern. One plausible explanation is that the signal outran the supplies — see what it needs to work. Other possibilities: novelty wearing off, the histamine response, or something unrelated. Change one thing at a time to find out.
How long before I notice anything?
The fuel-switching half starts fast. The capacity half takes weeks. Most reports describe subtle shifts around weeks 2–4, with markers moving over 4–6 weeks.
Why does it make me flush?
Mast cell activation releasing histamine, most likely. It often settles after the first few injections. Injecting more slowly helps.
Will it hurt muscle gains?
At moderate doses the effect is small. At higher doses, AMPK activation suppresses mTOR, which drives muscle protein synthesis.
Can I take it with other peptides?
People do. There's no human data on any combination, so nobody can tell you how they interact.
